Thompson Street Capital Partner’s Vector Laboratories Expands Bioconjugation Capabilities with the Acquisition of Quanta BioDesign

St. Louis-based private equity firm, Thompson Street Capital Partners (TSCP), announced today the acquisition of Quanta BioDesign by Vector Laboratories, a portfolio company of TSCP. Quanta BioDesign is known for their patented dPEG® technology, which enables advanced bioconjugate and payload delivery design for life science and biopharma applications. This acquisition further enhances Vector Laboratories' capabilities in bioconjugation and expands its portfolio of bioconjugation linkers and dyes.

The acquisition of Quanta BioDesign aligns with Vector Laboratories' long-term strategic vision of accelerating scientific discovery in the life science industry and driving transformational treatments and approaches for biopharma companies. By incorporating Quanta BioDesign's innovative cross-linking and labeling chemistries enabled by dPEG® technology, Vector Laboratories aims to revolutionize therapeutic and diagnostic development.

Lisa V. Sellers, CEO of Vector Laboratories, expressed excitement about the acquisition and stated, "It also builds on our recent acquisition of Click Chemistry Tools and Fluoroprobes and goes beyond standard linker capabilities to serve broader industrial segments, expanding what’s possible for customers in manufacturing components for their end products. It truly demonstrates a new level of flexibility in what they can accomplish with our offerings."

Quanta BioDesign, based in Plain City, OH, is dedicated to developing and commercializing an extensive line of dPEG®-based products for drug discovery and diagnostic development programs. Their technology allows for new approaches in therapeutic and diagnostic development, offering companies involved in these fields an innovative solution.

J.C. Wetzel, TSCP Managing Director, expressed enthusiasm about the growth opportunities this acquisition presents for Vector Laboratories. Wetzel said, "We’re excited about the opportunity to continue executing against Vector Laboratories’ long-term growth strategy by bringing cutting-edge technology to an expanding customer base, increasing its range of products and services, and ultimately impacting the important work of biopharmaceutical companies developing the next generation of treatment options."

This acquisition comes after Vector Laboratories' earlier acquisitions of Click Chemistry Tools and Fluoroprobes earlier this year. Vector Laboratories has a strong history of innovation in the field of labeling and detection technologies. They were the first to commercialize avidin-biotin enzyme complex kits for immunohistochemistry and antifade mounting media for immunofluorescence. Over four decades, Vector Laboratories has introduced more than 600 reliable reagents and kits.

About Thompson Street Capital Partners:

Thompson Street Capital Partners (TSCP) is a private equity firm based in St. Louis, Missouri, with a focus on investing in middle market businesses led by founders. TSCP has a strong presence in the Life Sciences & Healthcare Services, Software & Technology, and Business Services & Consumer Products sectors. With over 200 acquisitions and managing more than $4.5 billion since its establishment in 2000, TSCP partners with management teams to drive growth through organic strategies and complementary acquisitions.